UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

14 A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

Read More Share:

Oct

15 Powering the dreams of people impacted by myasthenia gravis (MG)

Read More Share:

Oct

15 UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

Read More Share:

Oct

14 UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

Read More Share:

Oct

11 UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Read More Share:

Sep

30 UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Read More Share:

Sep

27 UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Read More Share:

Sep

25 UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

Read More Share:

Sep

23 UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Read More Share:

Sep

23 Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community

Read More Share:

Categories

Archives

Nov

14

A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

Oct

15

Powering the dreams of people impacted by myasthenia gravis (MG)

Oct

15

UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

Oct

14

UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

Oct

11

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Sep

30

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Sep

27

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Sep

25

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

Sep

23

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Sep

23

Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Nov

14

A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

Oct

15

Powering the dreams of people impacted by myasthenia gravis (MG)

Oct

15

UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

Oct

14

UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

Oct

11

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Sep

30

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Sep

27

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Sep

25

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

Sep

23

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Sep

23

Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact